Lidocaine Infusion in Radical Cystectomy

• Status: Completed
• Trial end date: 2018-07-20
• Target enrollment: 0
• Participant gender: All

Summary

Radical cystectomy (RC) remains the gold standard for treatment of patients with muscle invasive bladder cancer, or recurrent high grade non-muscle invasive bladder cancer. Nowadays, enhanced recovery pathway is used to decrease morbidity and improve acute rehabilitation after RC. Postoperative ileus is the most frequent reason for prolonged hospital stay following cystectomy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• 45-75 yr ASA class I,II, and III Elective radical cystectomy

Exclusion Criteria:

• Allergy to the study medication, pre-existing chronic pain at any site requiring treatment, Psychiatric disease, hepatic or renal impairment, seizure disorder requiring medication within the previous 2 years